177Lu-PSMA-617 (Pluvicto) for the Treatment of Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Super Scan Bone Scan
Latest Information Update: 21 May 2025
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 21 May 2025 New trial record